Gilead’s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints
Published
Shares of Gilead Sciences Inc. GILD, tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it…
#gileadsciencesinc #gild #nsclc #gilead #trodelvy #merdadparsey